Abstract
BackgroundAn increasing number of studies have reported circular RNAs (circRNAs) as new potential biomarkers for the prognosis of gliomas. However, the overall prognostic value of circRNAs for glioma remains unclear. Therefore, this study is the first comprehensive evaluation of the clinicopathological and prognostic value of dysregulated circRNAs in the treatment of glioma patients.MethodsWe systematically reviewed the online databases of PubMed, Web of Science, EMBASE, and Cochrane Library to identify studies that explored the relationship between circRNA expression and clinicopathological and prognostic factors in glioma through April 11, 2020. The quality of the included studies was evaluated by the Newcastle-Ottawa Scale (NOS) checklists. Clinicopathological features were assessed by pooled odds ratios (ORs) and 95% confidence intervals (CIs), and overall survival (OS) was assessed by hazard ratios (HRs) and 95% CIs.ResultsTwenty-four eligible studies, including 22 studies of clinicopathological features, 1 diagnostic study, and 18 studies of prognosis, that included a total of 1390 patients were ultimately included in this study. Meta-analysis showed that highly expressed oncogenic circRNAs were significantly related to poor clinicopathological features (age: P = 0.026; tumor size: P ≤ 0.001; tumor grade: P ≤ 0.001; KPS: P = 0.012) and worse overall survival (OS) (HR = 2.01, 95% CI: 1.61–2.50, P ≤ 0.001). Moreover, we found that highly expressed tumor-suppressor circRNAs were related to better clinicopathological features (gender: P = 0.042; age: P = 0.014; tumor size: P = 0.022; tumor grade: P ≤ 0.001) and longer OS (HR = 2.70, 95% CI: 1.82–3.99, P ≤ 0.001).ConclusionsIn conclusion, there is a significant correlation between the dysregulated expression of circRNAs and the clinicopathology and prognosis of glioma patients.
Highlights
An increasing number of studies have reported circular RNAs as new potential biomarkers for the prognosis of gliomas
Literature retrieval strategy We carefully reviewed the PubMed, EMBASE, Cochrane Library, and Web of Science databases for relevant articles that studied the clinical value, including the assessment of pathological features, diagnosis, and prognosis, of Circular RNA (circRNA) expression in glioma patients before April 11, 2020
24 eligible studies, including 22 studies of clinicopathological features [10, 14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34], 1 study of diagnostics [35], and 18 studies of prognosis [10, 14,15,16,17,18,19,20,21,22,23,24,25,26,27,28, 35, 36], including a total of 1390 glioma patients were included in this study
Summary
An increasing number of studies have reported circular RNAs (circRNAs) as new potential biomarkers for the prognosis of gliomas. This study is the first comprehensive evaluation of the clinicopathological and prognostic value of dysregulated circRNAs in the treatment of glioma patients. With the development of highthroughput sequencing technology, research on the molecular basis of cancer has advanced, but the pathogenesis and biomarkers of gliomas are still unclear [3,4,5]. Studies have shown that circRNA can act as a “molecular sponge” to adsorb microRNAs (miRNAs) to regulate gene expression, and can play a role in directly regulating transcription and interfering with splicing mechanisms, so we believe that circRNA is closely related to the existence and development of cells like long non-coding RNAs [7,8,9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
